POS0657 GEOGRAPHIC VARIATION OF SAFETY IN THE FILGOTINIB RHEUMATOID ARTHRITIS PROGRAM

• Published in: Annals of the rheumatic diseases Vol. 80; no. Suppl 1; pp. 569 - 570
• Main Authors: Combe, B., Matsubara, T., Pechonkina, A., Tan, Y., Yin, Z., Hong, J., Besuyen, R., Gomez-Centeno, A., Buch, M.H.
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier B.V 01.06.2021; Elsevier Limited
• Subjects: Adverse events; Enzyme inhibitors; Geographical variations; Herpes zoster; Janus kinase; Patients; Placebos; Rheumatoid arthritis; Stockholders; Thromboembolism; Central America; Eastern Europe; Asia; North America; Western Europe

The Janus kinase-1 preferential inhibitor filgotinib (FIL) improved signs and symptoms of rheumatoid arthritis (RA) in the FIL clinical program.1–3 To assess FIL safety across regions. This was an analysis of patients (pts) meeting 2010 ACR/EULAR RA criteria in pooled phase (P)2 DARWIN 1–2 (D1–2), P...